SUDA Pharmaceuticals (ASX:SUD) Presentation, FNN Investor Event, September 2019, Sydney

Company Presentations

SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director and CEO, Stephen Carter presents on the company's portfolio and the benefits of reformulating and delivering medication through the oral mucosa at FNN's Investor Event.

Key points:

  • World leader in reformulating and delivering medication through oral spray
  • Has increased bioavailability up to 95 per cent
  • This is a major step forward in the evolution of drug delivery technology
  • Faster, potentially smaller doses & safer delivery for ex-blockbuster drugs
  • Technology validated with licensing deals with Teva and Mitsubishi
  • Robust intellectual property portfolio with over 50 patents

For more, watch Managing Director and CEO Stephen Carter present.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.